Diabetic Macular Edema (DME)- Pipeline Insight, 2026

DelveInsight's, "Diabetic Macular Edema (DME)- Pipeline Insight, 2026" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diabetic Macular Edema (DME) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Diabetic Macular Edema (DME): Understanding

Diabetic Macular Edema (DME): Overview

Diabetic Macular Edema (DME) is a major sight-threatening complication of diabetic retinopathy and a leading cause of visual impairment among individuals with diabetes. It is characterized by the accumulation of fluid within the macula, resulting in retinal thickening and disruption of the retinal structures responsible for central vision. Chronic hyperglycemia, prolonged duration of diabetes, hypertension, and dyslipidemia are important risk factors associated with the development and progression of DME. The increasing global prevalence of diabetes is expected to contribute to a continued rise in the burden of DME.

The pathogenesis of DME is multifactorial and involves metabolic, vascular, inflammatory, and neurodegenerative mechanisms. Persistent hyperglycemia promotes oxidative stress, formation of advanced glycation end products, protein kinase C activation, and inflammatory signaling, ultimately causing dysfunction of retinal endothelial cells and pericytes and breakdown of the blood-retinal barrier. Increased expression of vascular endothelial growth factor (VEGF), together with other inflammatory mediators, increases retinal vascular permeability and promotes leakage of plasma components into the retinal tissue. Consequently, fluid accumulation and cystoid changes develop within the macula, leading to retinal thickening and progressive impairment of visual function.

Diagnosis and monitoring of DME rely primarily on ophthalmic examination and retinal imaging, with optical coherence tomography (OCT) playing a central role in contemporary clinical practice. OCT provides high-resolution, non-invasive visualization of retinal morphology and enables assessment of retinal thickness, intraretinal cysts, subretinal fluid, and other structural changes. Fluorescein angiography can additionally identify areas of retinal vascular leakage and remains useful in selected patients. Importantly, morphological changes observed on OCT do not always correlate directly with visual acuity, contributing to ongoing discussion regarding disease classification, treatment response, and individualized treatment decisions.

Management of DME has been transformed by intravitreal anti-VEGF therapy, which remains the cornerstone of treatment for center-involving DME with visual impairment. Agents targeting VEGF reduce vascular leakage and can substantially improve or stabilize vision; however, treatment often requires repeated intravitreal injections, and some patients demonstrate incomplete response, recurrence, or limited durability. Corticosteroids, laser photocoagulation, and other approaches may be considered in selected patients, particularly those with persistent or treatment-resistant disease. Recent research is increasingly focused on longer-acting therapies, dual-pathway and multi-target approaches, novel anti-inflammatory mechanisms, and individualized treatment strategies aimed at reducing injection burden while maintaining visual outcomes.

"Diabetic Macular Edema (DME)- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Macular Edema (DME) pipeline landscape is provided which includes the disease overview and Diabetic Macular Edema (DME) treatment guidelines. The assessment part of the report embraces, in depth Diabetic Macular Edema (DME) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Macular Edema (DME) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Macular Edema (DME) R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Macular Edema (DME).

Diabetic Macular Edema (DME) Emerging Drugs Chapters

This segment of the Diabetic Macular Edema (DME) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Macular Edema (DME) Emerging Drugs

• MK-8748: Merck

MK-8748 (also known as Tiespectus, EYE201) is a novel investigational bispecific antibody with a dual mechanism that directly activates the Tie2 pathway and inhibits VEGF with the goal of stabilizing retinal and choroidal blood vessels and reducing fluid accumulation in the macula. Preclinical and early clinical evidence indicate that dual pathway modulation may help improve vascular stability in the retina and support vision preservation in patients with certain vascular retinal diseases. Currently, the drug is in the Phase III stage of its development for the treatment of Diabetic Macular Edema.

• Rivasterat: Curacle

CU06-1004 (Rivasterat) is an investigational oral endothelial dysfunction blocker being developed for diabetic macular edema (DME). At the 4th Asia Retina Congress, the company presented Phase IIa results from a U.S. study involving 67 patients, demonstrating improvements in best-corrected visual acuity (BCVA) across all dose groups (100, 200, and 300 mg), with patients receiving the 300 mg dose and having lower baseline vision achieving a maximum improvement of 5.8 ETDRS letters after 12 weeks. Central subfield thickness remained stable, while post hoc analyses showed dose-dependent improvements in retinal fluid and photoreceptor damage. No drug-related serious adverse events were reported. Based on these findings, Curacle announced that it would finalize its Phase IIb and Phase III development strategy through a US FDA Type C meeting, with the aim of accelerating global development and potential partnering opportunities.

• FT-003: Frontera Therapeutics

FT-003 Injection is a rAAV-based gene therapy developed to target retinal cells, enabling them to produce a humanized recombinant fusion protein homologous to aflibercept. This protein inhibits vascular endothelial cell proliferation and reduces vascular permeability, delivering therapeutic benefits. Preclinical data suggest FT-003 could provide long-lasting effects with a single administration. According to the company's pipeline the drug is in the Phase II stage of its development for the treatment of DME.

• OCU200: Ocugen

OCU200 is a recombinant fusion protein that consists of two parts connected by a linker: tumstatin, the active component, acts as an anti-inflammatory, anti-VEGF agent by binding to integrin receptors; and transferrin, which targets the drug to the choroid and retina by binding transferrin receptors on endothelial cells. These features will potentially enable OCU200 to reduce the vascular permeability, inflammation, and neovascularization that drive the pathophysiology of DME. In January 2025, Ocugen announced that the first patient has been dosed in the OCU200 Phase I clinical trial for diabetic macular edema.

Diabetic Macular Edema (DME): Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Macular Edema (DME) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Diabetic Macular Edema (DME)
• There are approx. 70+ key companies which are developing the therapies for Diabetic Macular Edema (DME). The companies which have their Diabetic Macular Edema (DME) drug candidates in the most advanced stage, i.e. phase III include, Merck.
• Phases

DelveInsight's report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Diabetic Macular Edema (DME) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Macular Edema (DME): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Macular Edema (DME) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Macular Edema (DME) drugs.

Diabetic Macular Edema (DME) Report Insights

• Diabetic Macular Edema (DME) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Macular Edema (DME) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Macular Edema (DME) drugs?
• How many Diabetic Macular Edema (DME) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Macular Edema (DME)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Macular Edema (DME) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Macular Edema (DME) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck
• Curacle
• Frontera Therapeutics
• Ocugen
• Kodiak Sciences
• Regenxbio Inc.
• Ocular Therapeutix
• Bayer
• RemeGen
• Roche
• Ocuphire Pharma
• Adverum Biotechnologies
• Boehringer Ingelheim

Key Products

• MK-8748
• Rivasterat
• FT-003
• OCU200
• KSI-301
• RGX 314
• OTX-TKI
• Runcaciguat
• RC 28 E
• RG7774
• APX3330
• ADVM-022
• Faricimab
• BI 764524